Subcortical white matter (WM) stroke accounts for 25% of all strokes and is the second leading cause of dementia. Despite such clinical importance, we still do not have an effective treatment for ischemic WM stroke, and the mechanisms of WM postischemic neuroprotection remain elusive. 3K3A-activated protein C (APC) is a signaling-selective analogue of endogenous blood protease APC that is currently in development as a neuroprotectant for ischemic stroke patients. Here, we show that 3K3A-APC protects WM tracts and oligodendrocytes from ischemic injury in the corpus callosum in middle-aged mice by activating protease-activated receptor 1 (PAR1) and PAR3. We show that PAR1 and PAR3 were also required for 3K3A-APC’s suppression of post–WM stroke microglia and astrocyte responses and overall improvement in neuropathologic and functional outcomes. Our data provide new insights into the neuroprotective APC pathway in the WM and illustrate 3K3A-APC’s potential for treating WM stroke in humans, possibly including multiple WM strokes that result in vascular dementia.
Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C
Disclosures: J.H. Griffin reported a patent to US 7,498,305 licensed "ZZ Biotech LLC"; and is a consultant for ZZBiotech LLC. B.V. Zlokovic is a founder of ZZ Biotech LLC, a biotechnology company with a mission to develop APC and its functional mutants for the treatment of stroke and other neurological disorders. No other disclosures were reported.
- Award Id(s): R01NS117827,R01NS090904,R01HL142975
- Views Icon Views
- Share Icon Share
- Search Site
Mikko T. Huuskonen, Yaoming Wang, Angeliki Maria Nikolakopoulou, Axel Montagne, Zhonghua Dai, Divna Lazic, Abhay P. Sagare, Zhen Zhao, Jose A. Fernandez, John H. Griffin, Berislav V. Zlokovic; Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. J Exp Med 3 January 2022; 219 (1): e20211372. doi: https://doi.org/10.1084/jem.20211372
Download citation file: